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In recent decades, there has been a significant increase in the incidence of fungal diseases. Certain fungal 
diseases cause cutaneous lesions and in the usual treatment, generally administred orally, the drug reaches 
the site of action with difficulty and its concentration is too low. An approach much explored in recent years 
is the development of nanotechnology-based drug delivery systems, and microemulsions (ME) and liquid 
crystals (LC) are promising. ME and LC were developed with oleic acid or copaiba oil as the oil phase, 
propoxyl (5OP) ethoxyl (20 OE) cetyl alcohol as surfactant and water. An analytical method to assess 
the incorporation of fluconazole (FLU) in the systems under study was validated according to guidelines 
of the International Conference on Harmonization (ICH) guidelines and the Brazilian Food, Drug and 
Sanitation Agency (ANVISA). The method was conducted on a C18-RP column (250 × 4.6 mm i.d.), 
maintained at room temperature. The mobile phase consisted of acetonitrile and water (50:50, v/v), run 
at a flow rate of 1.0mL/min and using ultraviolet detection at 210nm. The chromatographic separation 
was obtained with a retention time of 6.3min, and was linear in the range of 20-400 µg/mL (r2=0.9999). 
The specificity showed no interference of the excipients. The accuracy was 100.76%. The limits of 
detection and quantitation were 0.057 and 0.172 µg.mL-1, respectively. Moreover, method validation 
demonstrated satisfactory results for precision and robustness. The proposed method was applied for 
the analysis of the incorporation of FLU in ME and LC, contributing to improve the quality control and 
to assure the therapeutic efficacy.
Uniterms: Nanotehcnology. Microemulsions. Liquid crystals. High-performance liquid chromatography/
qualitative analysis. Fluconazole.
Nas últimas décadas, houve aumento significativo na incidência de doenças fúngicas. Certas doenças 
fúngicas provocam lesões cutâneas, sendo que no tratamento usual, geralmente administrado por via oral, 
o medicamento chega ao local de ação com dificuldade, em concentração muito baixa. Uma abordagem 
muito explorada nos últimos anos é o desenvolvimento de sistemas de administração de fármacos 
baseados em nanotecnologia, como as microemulsões (ME) e cristais líquidos (LC). ME e LC foram 
desenvolvidos com o ácido oleico ou óleo de copaíba como fase oleosa, álcool cetílico propoxilado (5 OP) 
e etoxilado (20 OE) como tensoativo e água. Método analítico para avaliar a incorporação de fluconazol 
(FLU) nos sistemas em estudo foi validado de acordo com as diretrizes da Conferência Internacional de 
Harmonização (ICH) e Agência Nacional de Vigilância Sanitária (ANVISA). O método foi desenvolvido 
empregando coluna C18-RP (250 x 4,6 mm id), mantida à temperatura ambiente. A fase móvel consistiu de 
acetonitrila e água (50:50, v/v), executado a uma taxa de fluxo de 1,0 mL/min e com detecção ultravioleta a 
210 nm. A separação cromatográfica foi obtida com o tempo de retenção de 6,3min, e mostrou-se linear no 
intervalo de 20-400 µg/mL (r2=0,9999). Pelo estudo de especificidade, observou-se não interferência dos 
excipientes. A precisão foi 100,76%. Os limites de detecção e de quantificação foram 0,057 e 0,172 µg.mL-1,  
respectivamente. Além disso, a validação do método demonstrou resultados satisfatórios para a precisão 
e robustez. O método proposto foi aplicado para a análise da incorporação do FLU em ME e cristais 
líquidos, contribuindo para aumentar o controle de qualidade e garantir a eficácia terapêutica.
Unitermos: Nanotecnologia. Microemulsões. Cristais líquidos. Cromatografia líquida de alta eficiência/
análise qualitativa. Fluconazol.
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INTRODUCTION
Fungal infections are considered a major problem 
for public health. A significant group of such infections 
are the dermatomycoses, involving the skin, especially the 
stratum corneum, and appendages such as nails, hair and 
mucous membranes (oral and vaginal) (Negroni, 2010; 
Erchiga, Fiorencio, 2005; Bachhav, Patrale, 2009).
Fluconazole – FLU (Figure 1) is a white, slightly 
soluble in water, soluble in ethanol, methanol and acetone 
and very slightly soluble in toluene. The presence of two 
triazole rings in its structure is responsible for its reduced 
lipophilicity (Dash, Elmquist, 2001). Its mechanism of 
action, like that of the other azoles, is related to its ability 
to alter the membrane permeability of yeasts and other 
fungi by inhibiting the synthesis of ergosterol. Inhibition 
of P-450 lanosterol 14-alpha-demethylase dependent 
causes accumulation of sterols methylated depletion 
ergosterol and inhibition of cell growth (Alnaim et al., 
2007; Jovanović et al., 2005; Pore et al., 2006).
Given the growing cost of fungal infections to the 
public health system, and highlighting the important role of 
azole antifungal agents, it is necessary to seek alternative 
administration route for these drugs in the treatment of 
fungal diseases, so as to increase their bioavailability 
efficiency and thus their therapeutic and to provide 
clinicians and patients with a greater diversity of treatment.
Strategies currently being investigated to overcome 
these limitations include the design and the development 
of drug delivery systems that can improve the efficacy 
of existing drugs. Topical drug delivery systems may 
contribute to the enhancement of the current antifungal 
therapy. Nanotechnology-based drug delivery systems 
such as liposomes, solid lipid nanoparticles, micro and 
nanoparticles, microemulsions (ME) and liquid crystals 
(LC) can modify the drug release profile, improve drug 
stability, increase the residence time of the drug at the 
site of action and the ready solubilization of drugs in 
these materials (Gupta, Vyas, 2012; El-Nesr et al., 2010; 
Gabboun et al., 2001; Peira et al., 2001).
ME are thermodynamically stable systems and 
isotropic systems, composed of an oil phase, an aqueous 
phase and a surfactant and/or co-surfactant, their properties 
facilitate the solubilization of lipophilic drugs, enabling 
their incorporation, if desired, at concentrations higher than 
that required at the target (Wei et al., 2012; Warisnoicharoen 
et al., 2000; Holmberg et al., 2002; Kreilgaard, 2002). 
The interaction of the drug with the system also provides 
controlled drug release and targeting of the site of action; 
ME are a type of formulation that can increase penetration 
through the stratum corneum (Huang et al., 2008; Alvarez-
Figuereo, Blanco-Méndez, 2001). This can occur by the 
following mechanisms: the composition and structure 
of these systems allow greater quantities of drug to be 
incorporated than other, conventional, topical formulations 
such as lotions, creams and gels. It can increase the 
solubility of drugs poorly soluble in water, via the oil phase, 
it can enhance drug stability, modify the diffusion barrier 
of the skin and promote drug release into the skin, without 
leading to significant irreversible changes in the skin barrier 
function (Baroli et al., 2000; Hoeller et al., 2008; Heuschkel 
et al., 2008).
LC are thermodynamically stable, optically isotropic, 
transparent and condensed structures that are both solid and 
liquid; thus, they are also known as mesophases (Mainardes 
et al., 2011; Formariz et al., 2005; Müller-Goymann, 2004). 
These systems combine the properties of both liquid and 
solid states and can be formed from the addition of solvents 
(Müller-Goymann, 2004). Their stability can be checked 
by varying the temperature (thermotropic liquid crystals) 
(Chorilli et al., 2011). The types of liquid crystals that can 
be formed are (liquid crystal) lamellar, hexagonal or cubic 
phases (Alam, Shrestha, Aramaki, 2009). The lamellar 
phase is formed by parallel layers of surfactant, aqueous 
and oil phases, which form one-dimensional networks. In 
the hexagonal phase, cylinders of surfactant molecules are 
formed and the oil phase may be present either inside the 
cylinders or in the continuous phase of the system. The cubic 
phase is the most viscous and has been observed mainly in 
water/surfactant or surfactant-like lipid systems or water/
surfactant/oil ternary systems (Alam, Shrestha, Aramaki, 
2009). Some authors have experimented with four different 
organizational arrangements of lamellar liquid crystal 
phases and three different arrangements of the cubic phases 
(Mannock et al., 2007; Chorilli et al., 2011).
LC-based drug delivery systems have been shown 
to increase the permeation of drugs because of the high 
concentrations of surfactants. The surfactants are able 
to destabilize the lipid layer of the skin, forming small 
pores in this structure (Kreilgaard, 2002). Höller, Valenta 
(2007) studied the solubility, rheological behaviour and 
FIGURE 1 - Chemical structure of fluconazole.
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permeation of several drugs from LC of the cubic phase, 
including FLU. The results showed that the incorporation 
of FLU in the system did not alter the rheological behavior 
of the formulation, and the drug was retained longer in the 
skin after skin permeation test.
Analytical methods employed in the quantitative 
determination of drug delivery systems play an important 
role in the assessment of pharmaceutical preparations, 
HPLC being the most frequently used method. To 
guarantee the quality of commercial products, the 
development and validation of analytical methods are 
crucial for the pharmaceutical industry (Apostol et al., 
2012). The methods for quantitation and detection must 
be robust, precise and rapid and are essential in the 
development, process monitoring and quality control of 
pharmaceuticals. Analytical validation is necessary for the 
routine quality control of products, so that reliable results 
can be satisfactorily interpreted (Shabir, 2003; ICH-Q2B, 
2005).
The validation of an analytical methodology is 
useful to demonstrate that the method is suitable for 
its intended purpose, to guarantee that every future 
measurement will be close enough to the unknown true 
value, for the content range of the analyte in the sample, 
and to ensure that the method meets the requirements of 
analytical methods, producing reliable results (Carvalho 
et al., 2009; Cinto et al., 2009). Assays based on HPLC 
are very commonly used to measure the quality of drugs 
and, according to ICH, certain parameters must be checked 
to validate the analytical method: linearity, specificity, 
accuracy, precision (inter and intraday), limit of detection 
(LOD), limit of quantitation (LOQ) and robustness (ICH-
Q2B, 2005; González, Herrador, 2007; Hofer et al., 2007).
Sasongko et al. (2003) developed a method that 
used HPLC to assay in a form taken FLU orally. Ayub et 
al. (2007) developed and validated an assay to measure 
the permeation of FLU from emulsions applied to the skin. 
Bachhav, Patravale (2009) validated a method of assaying 
FLU in released from microemulsions for vaginal use. 
However, no methodology has been developed to quantify 
fluconazole incorporated into ME or LC for cutaneous 
administration.
In light of this, the aim of this work was to validate 
an analytical methodology by HPLC to determine the 
amount of FLU incorporated in ME and LC.
MATERIAL AND METHODS
Equipment
The equipment used was a Varian HPLC with a 
ProStar 330 UV-VIS PDA detector and Rheodyne VS 125 
injector with a Varian ProStar® 410 autosample.
Chemicals
To formulate the ME, two copaiba oil were utilized, 
first copaiba oil (CO) was bought from cooperative in 
Brazil, the second from Sigma (OS). Fluconazole was 
purchased from Purifarma and oleic acid (OA) from Synth. 
Propoxyl (5OP) ethoxyl (20 OE) cetyl alcohol (PROC, 
Croda) was used as surfactant and the water was purified 
with a Milli Q Plus.
Development of microemulsion (ME) and liquid 
crystal (LC) to incorporation of FLU
In order to investigate the ME and LC regions, a 
ternary phases diagram was constructed, containing as oil 
phase copaiba oil obtained of cooperatives of Acre (Brazil) 
(CO), copaiba oil purchased from Sigma (OS) or oleic acid 
(OA). The second component was the surfactant propoxyl 
(5OP) ethoxyl (20 OE) cetyl alcohol (PROC) and the 
third was water. A fixed concentration of FLU (1%) was 
used. The compositions chosen for of the nanostructured 
systems are shown in Table I.
Incorporation of FLU in formulations
The capacity of formulations to incorporate FLU 
was investigated by adding an excess of FLU powder (100 
mg/g) to the formulations being tested. After shaking for 
48 h at 25 ± 0.1 oC, samples were centrifuged at 360 g for 
20 min (Du Pont-Sorvall TC 6 centrifuge), to eliminate 
undissolved FLU. The supernatants were diluted with 
mobile phase and the FLU dissolved in it was measured 
by HPLC method.
Method validation
The analytical method was validated by HPLC, to 
determine the following parameters: linearity, specificity, 
accuracy, inter and intraday precision, limit of detection 
(LOD), limit of quantitation (LOQ) and robustness, 
following the guidelines of the International Conference 
on Harmonization (ICH) guidelines (ICH-Q2B, 2005) 
and the Brazilian Food, Drug and Sanitation Agency 
(ANVISA) (Brasil, 2003).
Linearity
In order to assess the validity of the assay, 100 
mg fluconazole was dissolved in acetonitrile/water 1:1 
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(mobile phase) in 100 mL volumetric flask (1 mg.mL-1). 
Appropriate aliquots of this solution were diluted with 
the mobile phase, yielding concentrations of 20.0, 
40.0, 50.0, 100.0, 150.0, 200.0, 250.0, 300.0, 350.0 and 
400.0 µg.mL -1.  Tripl icate preparat ions of  each 
concentration were performed. The results were subjected 
to regression analysis by a least-squares method to 
calculate the calibration equation and determination 
coefficient.
Specificity
The specificity was determined by measuring the 
total purity of the chromatographic peaks in samples 
of phosphate buffer pH 7.4 containing FLU in the 
concentration at 150 µg.mL-1 and in the formulations 
containing oleic acid (OA), copaiba oil (CO) bought 
locally or from Sigma (OS), respectively, with or without 
FLU. This assay was performed in triplicate.
Precision
Precision data for this validation were determined 
as recommended by ICH-Q2B (2005). Repeatability was 
calculated by assaying samples of 20.0, 200.0 and 400.0 
mg mL1 intra- and inter-day in three different days; results 
must be less than 5%. The RSD of peak areas (n = 3) was 
evaluated.
Accuracy
To confirm the accuracy of the proposed method, 
a sample of fluconazole working solution was prepared 
in triplicate at three different concentrations, 20, 40 and 
200 µg.mL-1, within the analytical curve.
Limit of detection (LOD), limit of quantitation (LOQ)
To determine the LOD and LOQ, three analytical 
curves were prepared at concentrations near the presumed 
LOQ. The LOD and LOQ were calculated from equations 
(1) and (2) as described by IHC-Q2B (2005).
 LOD= 3 (S.D ./a) (1)
 LOQ = 10(S.D ./a) (2)
where S.D is the standard deviation of the y-intercepts and 
S is the slope of the calibration curve.
Robustness
Robustness was assessed against the intervention of 
some variables related to quantitation and recovery of the 
drug like column (Phenomenex and Varian), HPLC (Varian 
and HP) and detector (DAD and UV). The chromatographic 
parameters monitored were capacity factor, tailing factor 
(peak symmetry) and theoretical plates.
Statistical analysis
The ANOVA and Tukey tests were carried out 
using the BioEstat 5.0 software. Statistical relevance was 
assumed at p < 0.05.
RESULTS AND DISCUSSION
Method validation
Linearity
Fluconazole eluted from the column was analyzed in 
the mobile phase (acetonitrile and water 1:1) by measuring 
TABLE I - Composition (%) of the formulations for the physical system
Components
Samples 
Oil phase 
(CO, OS or OA)
Surfactant Aqueous phase LC or ME
CO1
20 40 40
LC hexagonal
OS1 LC hexagonal
OA1 LC lamelar
CO2
30 40 30
LC lamelar
OS2 LC hexagonal
OA2 LC lamelar
CO3
40 40 20
LC lamelar
OS3 LC lamelar
OA3 ME
CO4 
50 40 10
ME
OS4 ME
OA4 ME
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absorbance at 210 nm, and the area under the peak was 
calculated. The analytical curve was obtained by averaging 
three curves and performing in triplicate for each dilution 
curve.
The method was evaluated by the determination 
coefficient and intercept, calculated in the corresponding 
statistical study (ANOVA; p<0.05). The curve showed a 
good linearity at these concentrations, the mean (RSD) 
slope and y-intercept being 0.0005 and 0.0012, with a 
determination coefficient (r2) of 0.9999. R2 values > 0.999 
and intercepts very close to zero confirmed the good 
linearity of the method (Brasil, 2003).
It can be seen that the coefficient of variation 
between the samples was less than 2.119% (Table II), 
fulfilling ANVISA requirement of lower than 5% in these 
analyses (Brasil, 2003).
Precision
Tests of repeatability (intra-day) and intermediate 
(inter-day),  precision were carried out at  three 
concentration levels, begin low (20 µg.mL-1), medium 
(200 µg.mL-1) and high (400 µg.mL-1). Table III shows 
the results for repeatability.
In the repeatability test, the CV among samples 
was calculated and the highest 1%, for the lowest 
concentration. This is an acceptable value. According to 
ANVISA and ICH the CV must not exceed 5% in these 
assays, as in the test of linearity (ICH-Q2B, 2005; Brasil, 
2003). In Table IV, the results of the inter-day precision 
test, done on three consecutive days, are shown.
Again, the values of coefficient of variation are 
within the ANVISA and ICH limit of 5% (ICH-Q2B, 
2005; Brasil, 2003). Therefore, the analytical method was 
sufficiently precise in both tests.
Accuracy
In  order  to  check  the  accuracy,  the  same 
concentrations as in the precision test were used and the 
results were analyzed as percent recovery of the sample. 
The results are shown in Table V.
TABLE II - Data used to evaluate the linearity
Theoretical 
Concentration 
(µg.mL-1)
Peak area 
(Au.min)*
Standard 
deviation CV (%)**
20 0.011087 0.00015 1.327
50 0.026787 0.00057 2.119
100 0.053352 0.00028 0.525
150 0.079218 0.00113 1.424
200 0.105514 0.00025 0.235
250 0.131502 0.00006 0.048
300 0.156485 0.00072 0.459
350 0.181283 0.00106 0.586
400 0.208915 0.00200 0.959
*Average of three curves. **CV-coefficient of variation, 
calculated from the mean and standard deviation of the areas 
obtained.
TABLE III - Results from the repeatability (intra-day precision) 
test
Theoretical 
Concentration 
(µg.mL-1)
Area* Standard deviation CV (%)
20 0.01096 1.09801.10-4 1.00162
200 0.10386 2.34862.10-4 0.22612
400 0.20392 1.58324.10-4 0.77639
*Average of three values. CV: coefficient of variation.
TABLE IV - Results from the intermediate precision test
Theoretical 
Concentration 
(µg.mL-1)
Area* Standard 
deviation
CV (%)
20 0.01104 1.29853.10-4 1.17604
200 0.10484 a8.48326.10-4 0.80914
400 0.20776 3.42698.10-3 1.64952
*Average of three values. CV, coefficient of variation.
TABLE V - Results for accuracy
Theoretical Concentration 
(µg.mL-1) Area* Standard deviation CV (%) Rec (%)
20 0.01111 7.51022.10-5 0.67589 99.12
200 0.10317 7.71213.10-4 0.74755 101.97
400 0.20362 1.20190.10-4 0.59026 101.21
*Average of three values. CV: coefficient of variation. Rec: recovery.
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The percent recovery values are shown in Table VI 
and they were all found to be between 99 and 102%. The 
results are well within the interval of recovery values 
approved by ANVISA, namely 80-120%. Moreover, the 
CV was less that 1%, being greatest at a concentration of 
200 µg.mL-1. The values coefficient of variation are thus 
ANVISA and ICH limit of 5% (ICH-Q2B, 2005; Brasil, 
2003).
Limits of detection (LOD) and quantitation (LOQ)
The detection limit is the smallest amount of the 
analyte that can be detected but not necessarily quantified, 
while the limit of quantitation is the smallest content of the 
analyte that can be analyzed with accuracy and precision 
(ICH-Q2B, 2005). The values of LOD and LOQ were 
0.057 and 0.172 µg.mL-1, respectively, indicating the 
excellent sensitivity of the analytical method.
Specificity and Selectivity
Figure 2 shows the chromatogram of a single injection 
of buffer containing FLU. It can be seen that the buffer did 
not interfere with in the analysis, as it did not affect the drug 
peak region. This assay was performed in triplicate.
The analysis of the formulations containing 
fluconazole (Figure 3) also showed no interference in the 
drug peak region.
TABLE VI - Content of fluconazole determined the formulations
Sample Sample mass (g) Peak* CC fluconazole 
(µg.mL-1)* SD CV (%) Content (mg/g)*
OA1 0.0656 0.08134 160.28 1.58 0.99 24.43
OA2 0.0577 0.0772 152.00 1.53 1.00 26.34
OA3 0.0500 0.07565 148.90 2.50 1.68 29.78
OA4 0.0576 0.07690 151.40 2.10 2.08 26.28
CO1 0.1074 0.07902 155.64 0.70 0.45 14.49
CO2 0.1073 0.07849 154.58 2.65 2.57 14.41
CO3 0.0836 0.07956 156.72 1.72 1.10 18.75
CO4 0.0838 0.08036 158.32 1.89 1.19 18.89
OS1 0.1250 0.07561 148.82 1.96 1.32 11.90
OS2 0.1254 0.07901 155.62 2.81 1.80 12.41
OS3 0.1251 0.07637 150.34 2.19 1.45 12.02
OS4 0.1250 0.07307 143.74 0.80 0.56 11.50
*Average of three values. CC - calculated concentration, SD - standard deviation, CV- Coefficient of variation.
FIGURE 2 - Chromatogram relating injection phosphate buffer pH 7.4 containing fluconazole (150μg.mL-1).
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FIGURE 3 - Chromatogram solution of selected formulations containing FLU (150μg.mL-1).
The specificity of an analytical method can be 
assessed by determining the chromatographic peak purity 
using a diode array detector (Brasil, 2003), which shows 
graphically and numerically the similarity of the spectrum 
of the peak of the substance of interest. The results indicate 
purity index of 0.99 in both cases, indicating the similarity 
of the peaks, that is, the chromatographic peak refers to 
the substance of interest, without interference.
Robustness
In this assay, the interference of certain parameters 
in the analytical results was assessed. It was found that 
changing the column make, type of HPLC or detector 
did not interference with the peak retention time or the 
drug recovery. The system suitability method acceptance 
criteria set in each validation run were: capacity factor 
< 2.0, tailing factor ≥ 2.0 and theorical plates > 2000. In 
all cases, the relative standard deviation (RSD) for the 
anlayte peak area for two consecutive injections was < 
2.0%. The values obtained are in agreement with the 
literature (ICH-2QB, 2005). Therefore, the method may 
be considered robust.
Incorporation of FLU in the formulations
Analyses were performed in triplicate and results 
expressed as the content of FLU in the formulation, in 
mg.g-1, as shown in Table VI. The concentration was 
calculated from the peak area by the equation and analytical 
curve obtained in the test of linearity: y=0.0005 x + 0.0012.
The statistical analysis showed that the difference 
between the incorporation of FLU into CO1, CO2, CO3, 
CO4, OS1, OS2, OS3 and OS4 was not statistically 
significant (p>0.05). On the other hand, OA1, OA2, 
OA3 and OA4 exhibited values of FLU incorporation 
significantly higher (p<0.05) than CO1, CO2, CO3, CO4, 
OS1, OS2, OS3 and OS4.
It was observed that the formulations with CO or CS 
as oil phase presented lower quantity of FLU incorporated 
when compared with formulations with OA as oil phase. 
This may be due to the complex composition of these oils, 
which contain various nonpolar components and other polar 
chains that hinder the solubilization of drugs such as FLU.
Veiga Junior, Pinto, and Maciel et al. (2005) claim 
that copaiba oil may vary in relation to the concentration 
and nature of diterpenes and sesquiterpenes present 
variations according to species, biological or abiotic 
factors. Thus, although the difference in the amount of 
FLU incorporated was not statistically significant in 
copaiba oils from different sources tested, since they have 
different amounts of terpenes, this could result in different 
affinities by drugs with different degrees of lipophilicity.
CONCLUSIONS
All validation parameters were satisfactory; the 
results showed that the method is suitable for quantitative 
analysis of FLU, consistent with the requirements of ICH 
and ANVISA, and thus providing a reliable analytical 
method. The proposed method was accurate in measuring 
the concentration of FLU in ME and LC.
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